Table 2.

Effect of protein kinase inhibitors on DA-stimulated phosphorylation of NR1 in nucleus accumbens slices

Treatment	[32P]phosphate-labeled NR1 (%)
A.
Control	26  ± 6
H-89	32  ± 5
Dopamine/nomifensine	100
H-89 + Dopamine/nomifensine	35  ± 4*
B.
Control	47  ± 9
Calphostin	54  ± 12
Dopamine/nomifensine	100
Calphostin C+ Dopamine/nomifensine	108  ± 29
C.
Control	29  ± 9
PDBu	100
Calphostin C + PDBu	26  ± 2**

Nucleus accumbens slices were prelabeled with [³²P]phosphate. Slices were incubated for a total of 20 min. A PKA inhibitor (H-89, 0.5 μm) or a PKC inhibitor (calphostin C, 1 μm) was added at 0 min, followed by addition of either PDBu (5 μm) at 15 min or DA (100 μm) plus nomifensine (10 μm) at 19 min. [³²P]phosphate incorporated into NR1 was determined as described in Materials and Methods. The data were calculated as percentage of radioactivity in stimulated slices and represent means ± SEM for three to five experiments (*p < 0.05 compared with dopamine/nomifensine; **p < 0.05 compared with PDBu; Student’s t test).